BRCA1

US Preventive Services Task Force recommends genetic testing for mutations in the cancer-related genes for more—but not all—women.

Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

The researchers catalogued 3,893 variants of the gene implicated in cancer using CRISPR.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

Researchers identify 72 novel genetic variants associated with breast cancer risk.

David Schwartz of the Illinois Institute of Technology-Chicago, Kent College of Law, discusses the impact of the US Supreme Court unanimously striking down Myriad Genetics' patent of human BRCA genes and tests to detect mutations in them.

The cancer-related protein BRCA1 is important for learning and memory in mice and is depleted in the brains of Alzheimer’s patients, according to a study.

Color Genomics announces a new, lower-cost BRCA mutation test, while Inserm and Quest Diagnostics reveal plans to pool patient data to investigate rare mutations.

In a large study, researchers find evidence to suggest that the type and location of a woman’s BRCA1/2 mutations may affect her cancer risk.

The Federal Court of Australia rejected an appeal of a ruling that allows companies to patent isolated human genes.

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing another competitor for patent infringement.

The breast cancer-associated gene may play a protective role in neural stem cells, a mouse study finds.

A judge declines Myriad Genetics’s request to block its competitors from selling BRCA tests.  

August 2013's selection of notable quotes

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement.

Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.

The Justices have decided that isolated sequences of human DNA are not eligible for patent protection, but rules that artificial sequences can be patented.